Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study.

OBJECTIVE - To report outcomes of patients with localised prostate cancer (PCa) managed with active surveillance (AS) in a standard clinical setting.

DESIGN - Single-centre, prospective, observational study.

SETTING - Non-academic, average-size hospital in Switzerland.

PARTICIPANTS - Prospective, observational study at a non-academic, average-size hospital in Switzerland. Inclusion and progression criteria meet general recommendations. 157 patients at a median age of 67 (61-70) years were included from December 1999 to March 2012. Follow-up (FU) ended June 2013.

RESULTS - Median FU was 48 (30-84) months. Overall confirmed reclassification rate was 20% (32/157). 20 men underwent radical prostatectomy with 1 recurrence, 11 had radiation therapy with 2 prostate-specific antigen relapses, and 1 required primary hormone ablation with a fatal outcome. Kaplan-Meier estimates for those remaining in the study showed an overall survival of 92%, cancer-specific survival of 99% and reclassification rate of 41%. Dropout rate was 36% and occurred at a median of 48 (21-81) months after inclusion. 68 (43%) men are still under AS.

CONCLUSIONS - Careful administration of AS can and will yield excellent results in long-term management of PCa, and also helps physicians and patients alike to balance quality of life and mortality. Our data revealed significant dropout from FU. Patient non-compliance can be a relevant problem in AS.

BMJ open. 2016 Feb 17*** epublish ***

Lukas J Hefermehl, Daniel Disteldorf, Kurt Lehmann

Division of Urology, Department of Surgery, Kantonsspital Baden, Baden, Switzerland. , Division of Urology, Department of Surgery, Kantonsspital Baden, Baden, Switzerland. , Division of Urology, Department of Surgery, Kantonsspital Baden, Baden, Switzerland.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe